Recorlev
Payments companies reported to CMS as associated with Recorlev. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Recorlev, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Recorlev
These are the largest totals companies reported as associated with Recorlev. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Elena Christofides | Columbus, OH | Endocrinology, Diabetes & Metabolism | $132,658.26 |
| Philip Rabito | New York, NY | $97,354.68 | |
| Ilja Hulinsky | Bridgeport, CT | Endocrinology, Diabetes & Metabolism | $79,090.29 |
| Firas Akhrass | San Antonio, TX | Endocrinology, Diabetes & Metabolism | $43,641.02 |
| Benjamin Brannick | Memphis, TN | Endocrinology, Diabetes & Metabolism | $40,544.04 |
| Saleemah Fahmi | Dallas, TX | Endocrinology, Diabetes & Metabolism | $24,568.87 |
| Lee Metchick | Deland, FL | Endocrinology, Diabetes & Metabolism | $23,143.88 |
| Maria Fleseriu | Portland, OR | Endocrinology, Diabetes & Metabolism | $20,881.15 |
| Brandy Biederman | Hixson, TN | Family | $20,180.87 |
| Jawaad Khokhar | Glen Burnie, MD | Endocrinology, Diabetes & Metabolism | $19,449.81 |
Prescribed Recorlev?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.